9 completed, 4 unknown, 3 terminated, 2 recruiting. 20 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 9, Unknown 4, Terminated 3, Recruiting 2, Withdrawn 2 |
| Phase 2 | 7 | Completed 3, Unknown 2, Recruiting 1, Terminated 1 |
Follow Carcinoid Tumor: new trials by email Literature Review of Carcinoid Tumor trials Research Report on Carcinoid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. RYZ401 - GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor | Phase 1 | Recruiting | RayzeBio, Inc. | 104 | 2025-12-03 | 2026-11-03 |
| Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) Lu-177-DOTATATE, Olaparib, Ga dotatate scanning - Gastroenteropancreatico Tumors, Neuroendocrine Tumors | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 56 | 2022-10-03 | 2026-10-16 |
| A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors Ga-68-DOTA-TOC, Siemens PET/MR scanner, Standard Siemens Software - Small Bowel Carcinoid Tumor | Phase 1 | Withdrawn | Massachusetts General Hospital | 2018-11-01 | 2019-06-21 | |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors surufatinib - Tumors | Phase 1 / Phase 2 | Completed | Hutchmed | 130 | 2015-11-01 | 2024-07-10 |
| 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) 68Ga-DOTATOC PET - Neuroendocrine Tumors, Carcinoid Tumors | Phase 1 | Terminated | Lale Kostakoglu | 71 | 2014-12-01 | 2017-05-03 |
| GA-68 DOTA-TOC of Somatostatin Positive Malignancies Computed Tomography (CT), Gallium Ga 68-Edotreotide, Magnetic Resonance Imaging (MRI) - Neuroendocrine Tumor, Paraganglioma | Phase 1 / Phase 2 | Terminated | University of California, San Francisco | 300 | 2014-06-23 | 2019-11-12 |
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography. - Neuroendocrine, Neuroendocrine Tumor | Phase 1 / Phase 2 | Unknown | Ochsner Health System | 250 | 2014-03-01 | 2014-01-17 |
| Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors 68Ga-DOTATOC PET/CT - Neuroendocrine Tumors, Carcinoid Tumors | Phase 1 / Phase 2 | Completed | Sue O'Dorisio | 223 | 2012-02-21 | 2021-07-27 |
| A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients TKM-080301 - Cancer, Neuroendocrine Tumors | Phase 1 / Phase 2 | Completed | Arbutus Biopharma Corporation | 68 | 2010-12-01 | 2019-01-16 |
| Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs Pasireotide LAR followed by Pasireotide LAR + Everolimus, Everolimus followed by Pasireotide LAR + Everolimus - Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System | Phase 1 | Completed | Novartis Pharmaceuticals | 36 | 2010-11-01 | 2020-12-21 |
| Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies Proton Therapy - Non-small Cell Lung Cancer, Small Cell Lung Cancer | Phase 1 | Terminated | M.D. Anderson Cancer Center | 30 | 2010-07-16 | 2020-01-02 |
| Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor RAD001 (everolimus, Afinitor®) - Neuroendocrine Tumors, Carcinoid Tumor | Phase 1 / Phase 2 | Unknown | Guangdong Provincial People's Hospital | 20 | 2010-07-01 | 2010-08-04 |
| A Study to Assess PV-10 Chemoablation of Cancer of the Liver PV-10 (10% rose bengal disodium) - Cancer Metastatic to the Liver, Hepatocellular Carcinoma | Phase 1 | Unknown | Provectus Biopharmaceuticals, Inc. | 78 | 2009-10-01 | 2022-11-02 |
| Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Sorafenib, RAD001 - Neuroendocrine Tumor, Carcinoid Tumor | Phase 1 | Completed | Dana-Farber Cancer Institute | 21 | 2009-07-01 | 2014-04-29 |
| Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors SOM230, RAD001 - Neuroendocrine Tumor, Carcinoid Tumor | Phase 1 | Completed | Dana-Farber Cancer Institute | 22 | 2008-10-01 | 2016-10-19 |
| ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Ultratrace iobenguane I 131 - Pheochromocytoma, Paraganglioma | Phase 1 | Completed | Molecular Insight Pharmaceuticals, Inc. | 24 | 2006-06-01 | 2011-10-12 |
| Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease Pasireotide - Carcinoid Tumor, Acromegaly | Phase 1 | Completed | Novartis Pharmaceuticals | 85 | 2006-06-01 | 2020-12-21 |
| Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features Seneca Valley Virus (biological agent) - Carcinoid, Neuroendocrine | Phase 1 | Unknown | Neotropix | 60 | 2006-04-01 | 2010-02-25 |
| Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Dacarbazine and bortezomib - Melanoma, Soft Tissue Sarcoma | Phase 1 | Completed | Virginia Commonwealth University | 17 | 2004-09-01 | 2016-08-18 |
Neuroendocrine Tumors (12) · Adenoma, Islet Cell (4) · Neuroblastoma (3) · Lung Neoplasms (2) · Medulloblastoma (2) · Melanoma (2) · Neoplasms (2) · Paraganglioma (2) · Pheochromocytoma (2) · Sarcoma (2) · Small Cell Lung Carcinoma (2) · Acromegaly (1) · Adrenal Cortex Neoplasms (1) · Adrenocortical Carcinoma (1)
Adenocarcinoma (20) · Carcinoma (20) · Neoplasms by Histologic Type (20) · Neoplasms, Germ Cell and Embryonal (20) · Neoplasms, Glandular and Epithelial (20) · Neoplasms, Nerve Tissue (20) · Neuroectodermal Tumors (20) · Neoplasms (18) · Neoplasms by Site (10) · Endocrine System Diseases (9) · Endocrine Gland Neoplasms (8) · Neuroendocrine Tumors (8) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Pancreatic Diseases (6)
Everolimus (4) · gallium Ga 68 dotatate (3) · pasireotide (2) · Biological Factors (1) · Bortezomib (1) · Capecitabine (1) · Dacarbazine (1) · Ga(III)-DOTATOC (1) · Magnetic Resonance Spectroscopy (1) · Octreotide (1) · Proton Therapy (1) · Radiation (1) · Radiotherapy (1) · Rose Bengal (1) · Sorafenib (1)
Dana-Farber Cancer Institute (2) · Novartis Pharmaceuticals (2) · Arbutus Biopharma Corporation (1) · Guangdong Provincial People's Hospital (1) · Hutchmed (1) · Lale Kostakoglu (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Molecular Insight Pharmaceuticals, Inc. (1) · National Cancer Institute (NCI) (1) · Neotropix (1) · Ochsner Health System (1) · Provectus Biopharmaceuticals, Inc. (1) · RayzeBio, Inc. (1) · Sue O'Dorisio (1)
United States (16) · Canada (2) · Germany (2) · Belgium (1) · China (1) · Italy (1) · Netherlands (1) · Norway (1)
Andrew Poklepovic, MD (1) · Daniel Gomez, MD (1) · Eric Wachter, PhD (1) · Frank I Lin, M.D. (1) · Jennifer Ang Chan, MD, MPH (1) · Jennifer Chan, MD, MPH (1) · Jordan Berlin, M.D. (1) · Lale Kostakoglu, MD, MPH (1) · Marjo Hahka-Kemppinen, MD, PhD (1) · Mark Kowalski, MD (1) · Ralph E Coleman, MD (1) · Rudin Charles, MD, PhD (1) · Sue O'Dorisio, MD (1)
PMID 18391430, PMID 22736724, PMID 23475104, PMID 24800725, PMID 28153957, PMID 29181270, PMID 37074571, PMID 39500789
2005 (1)